Chemo-immunotherapy for young people with bone or soft tissue sarcoma
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old
- You have a type of sarcoma (bone or soft tissue cancer) that has returned or not responded to at least one prior chemotherapy treatment
- Your tumor cells have a marker called GD2 (a protein on the cancer cells)
- You are generally active and able to do most daily activities (performance status 80-100%)
- Your heart, liver, kidneys, and blood counts are working well enough, as confirmed by tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
This trial uses lab-grown tumor samples from your child to test which chemotherapy drugs work best for their specific cancer. The goal is to find the most effective treatment by testing medicines on their tumor cells before giving them to your child.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests adding a drug called Dinutuximab Beta to standard chemotherapy for people with a newly diagnosed, high-risk type of Ewing sarcoma that has a certain marker (GD2) on the tumor cells. The goal is to see if this combination is safe and can help improve outcomes.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Hear when a new Bone Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.